AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 326385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone and polychemotherapy (oophorectomy plus modified five-drug 'Cooper' combination)
Number of subjects: 213
Study 326385 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone and polychemotherapy (diethylstilbestrol and cytostatic therapy)
Number of subjects: 213
Study 326385 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus progesterone
Number of subjects: 213
Study 326385 — intervention group
Group type: COMPARATOR
Intervention: Polychemotherapy alone (control group)
Number of subjects: 213
Study 30394240 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of CRP level during the initial follow-up interval (T1-T2)
Number of subjects: 208
Study 30394240 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CRP level
Number of subjects: 208
Study 29237420 — intervention group
Group type: EXPERIMENTAL
Intervention: Text and voice messages containing information and encouragement to undergo screening
Number of subjects: 400
Study 29237420 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control arm)
Number of subjects: 400
Study 26505681 — intervention group
Group type: EXPERIMENTAL
Intervention: XELIRI/FOLFIRI plus simvastatin (40 mg)
Number of subjects: 269
Study 26505681 — intervention group
Group type: COMPARATOR
Intervention: XELIRI/FOLFIRI plus placebo
Number of subjects: 269
Study 23411675 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable task with graded instability, practiced for about 1 hour.
Number of subjects: 0
Study 21323568 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel plus imatinib
Number of subjects: 88
Study 21323568 — intervention group
Group type: COMPARATOR
Intervention: docetaxel alone
Number of subjects: 88
Study 19762758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone
Number of subjects: 91
Study 19762758 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine
Number of subjects: 91
Study 17827829 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (20 mg/day)
Number of subjects: 0
Study 17827829 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (40 mg/day)
Number of subjects: 0
Study 15214905 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 8 weeks followed by calcipotriol ointment once daily for 4 weeks
Number of subjects: 972
Study 15214905 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-compound product (calcipotriol/betamethasone dipropionate) once daily for 4 weeks followed by calcipotriol ointment once daily on weekdays and the two-compound product once daily at weekends
Number of subjects: 972
Study 15214905 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol ointment twice daily for 12 weeks
Number of subjects: 972
Study 11816704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan 30 mg/day intramuscularly for 3 weeks followed by 100 mg/day orally for 20 weeks
Number of subjects: 242
Study 11816704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 11816704 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 242
Study 9522105 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor 25 mg/kg BID
Number of subjects: 245
Study 9522105 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate 15 mg/kg TID
Number of subjects: 245
Study 9522105 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 15 mg/kg TID
Number of subjects: 245
Study 8025984 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 40
Study 8025984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 2508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg/d
Number of subjects: 800
Study 2508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocopherol (vitamin E) 2000 IU/d
Number of subjects: 800
Study 2508608 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl 10 mg/d and Tocopherol (vitamin E) 2000 IU/d
Number of subjects: 800
Study 2508608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 324773 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (150‐200 mg daily)
Number of subjects: 27
Study 324773 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylbutazone (300‐400 mg daily)
Number of subjects: 27
Study 29313271 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-filtration plasmapheresis (DFPP) in addition to DMARDs (leflunomide and methotrexate)
Number of subjects: 72
Study 29313271 — intervention group
Group type: COMPARATOR
Intervention: DMARDs (leflunomide and methotrexate)
Number of subjects: 72
Study 27459586 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen receptor inhibitor monotherapy
Number of subjects: 110
Study 27459586 — intervention group
Group type: COMPARATOR
Intervention: Castration plus an androgen receptor inhibitor
Number of subjects: 110
Study 24595146 — intervention group
Group type: COMPARATOR
Intervention: 40 mg lidocaine
Number of subjects: 68
Study 24595146 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lidocaine
Number of subjects: 68
Study 24595146 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg lidocaine
Number of subjects: 68
Study 22459918 — intervention group
Group type: EXPERIMENTAL
Intervention: Dienogest (DNG)
Number of subjects: 0
Study 22459918 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate (LA)
Number of subjects: 0
Study 20117379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin + omega-3 fatty acids (4 capsules daily)
Number of subjects: 30
Study 20117379 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg daily
Number of subjects: 30
Study 18588670 — intervention group
Group type: COMPARATOR
Intervention: Medical practice group
Number of subjects: 274
Study 18588670 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent researcher group
Number of subjects: 274
Study 15801995 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin extended-release (ER) 1000 mg once daily for 5 days
Number of subjects: 485
Study 15801995 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin immediate-release (IR) 500 mg twice daily for 7 days
Number of subjects: 485
Study 11929392 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride, 10 mg q.d.s.
Number of subjects: 10
Study 11929392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 10385713 — intervention group
Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 60
Study 10385713 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ligation and sclerotherapy
Number of subjects: 60
Study 8873692 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium diet (240 mEq/day)
Number of subjects: 13
Study 8873692 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (20 mEq/day)
Number of subjects: 13
Study 2028396 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative telecobalt therapy
Number of subjects: 54
Study 2028396 — intervention group
Group type: COMPARATOR
Intervention: Postoperative electron therapy
Number of subjects: 54
Study 2028396 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG
Number of subjects: 54
Study 2028396 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 54
Study 6984983 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold cardioplegia with external cardiac cooling
Number of subjects: 50
Study 6984983 — intervention group
Group type: COMPARATOR
Intervention: Ischaemic arrest with mild systemic cooling to 32 degrees C
Number of subjects: 50
Study 31661034 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) by intensity modulated radiotherapy with simultaneous integrated boost (IMRT-SIB) involving 7 Gy × 3 fractions to the whole involved vertebra + 10 Gy × 3 fractions on the gross tumor volume (GTV)
Number of subjects: 330
Study 31661034 — intervention group
Group type: COMPARATOR
Intervention: Standard conventional radiotherapy involving 4 Gy × 5 fractions to the whole involved vertebra
Number of subjects: 330
Study 29489581 — intervention group
Group type: EXPERIMENTAL
Intervention: Socket shield technique
Number of subjects: 0
Study 29489581 — intervention group
Group type: COMPARATOR
Intervention: Conventional insertion technique
Number of subjects: 0
Study 26652921 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal translation of maxillary first premolar with 50 g of force
Number of subjects: 11
Study 26652921 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-moved maxillary first premolar)
Number of subjects: 11
Study 26652921 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal translation intervention
Number of subjects: 11
Study 25437588 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine gluconate (CHG)
Number of subjects: 100
Study 25437588 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 100
Study 22965457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 75
Study 22965457 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 75
Study 20510026 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced airway management
Number of subjects: 41
Study 20510026 — intervention group
Group type: COMPARATOR
Intervention: Conventional systemic therapy and management of airway (Control)
Number of subjects: 41
Study 17580145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS) with cyclosporine microemulsion
Number of subjects: 456
Study 17580145 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated mycophenolate sodium (EC-MPS)
Number of subjects: 456
Study 16383040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/100 cm2 Dermlin topical application
Number of subjects: 90
Study 16383040 — intervention group
Group type: COMPARATOR
Intervention: Topical application of silver sulfadiazine (SD - Ag) cream
Number of subjects: 90
Study 16383040 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/100 cm2 Dermlin treatment for diabetic foot ulcers
Number of subjects: 90
Study 16383040 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell culture with 20 g/L Dermlin
Number of subjects: 90
Study 16383040 — intervention group
Group type: COMPARATOR
Intervention: Topical application of silver sulfadiazine (SD - Ag) cream in animal test
Number of subjects: 90
Study 12031758 — intervention group
Group type: EXPERIMENTAL
Intervention: CR oxycodone 10 mg
Number of subjects: 50
Study 12031758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 10082174 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release capsule (300 mg sodium valproate)
Number of subjects: 24
Study 10082174 — intervention group
Group type: COMPARATOR
Intervention: Oral solution (300 mg sodium valproate)
Number of subjects: 24
Study 10082174 — intervention group
Group type: COMPARATOR
Intervention: Enteric-coated tablet (300 mg sodium valproate)
Number of subjects: 24
Study 7788460 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training
Number of subjects: 33
Study 7788460 — intervention group
Group type: COMPARATOR
Intervention: Social milieu treatment
Number of subjects: 33
Study 2140609 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric load of glucose
Number of subjects: 6
Study 2140609 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (25 mg)
Number of subjects: 6
Study 2140609 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal plasma beta endorphin level
Number of subjects: 6
Study 2140609 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study 2140609 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 6
Study 6816315 — intervention group
Group type: COMPARATOR
Intervention: TAM alone
Number of subjects: 82
Study 6816315 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM + FT
Number of subjects: 82
Study 31658070 — intervention group
Group type: EXPERIMENTAL
Intervention: Vojta approach
Number of subjects: 13
Study 31658070 — intervention group
Group type: COMPARATOR
Intervention: General exercise
Number of subjects: 13
Study 30308612 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive thoracolaparoscopic esophagectomy (RAMIE)
Number of subjects: 112
Study 30308612 — intervention group
Group type: COMPARATOR
Intervention: Open transthoracic esophagectomy (OTE)
Number of subjects: 112
Study 28182908 — intervention group
Group type: EXPERIMENTAL
Intervention: Training the social skill 'being able to demand'
Number of subjects: 40
Study 28182908 — intervention group
Group type: EXPERIMENTAL
Intervention: Training the social skill 'being able to say no'
Number of subjects: 40
Study 25782365 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical capsaicin application
Number of subjects: 80
Study 25782365 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal grill (TG) after capsaicin application
Number of subjects: 80
Study 25782365 — intervention group
Group type: COMPARATOR
Intervention: Thermal grill (TG) after vehicle control (ethanol) application
Number of subjects: 80
Study 25782365 — intervention group
Group type: EXPERIMENTAL
Intervention: Paradoxical heat sensation (PHS) after capsaicin application
Number of subjects: 80
Study 25782365 — intervention group
Group type: COMPARATOR
Intervention: Paradoxical heat sensation (PHS) after control application
Number of subjects: 80
Study 25782365 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection thresholds to cold and warm after capsaicin application
Number of subjects: 80
Study 25782365 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal pain threshold after capsaicin application
Number of subjects: 80
Study 23369724 — intervention group
Group type: EXPERIMENTAL
Intervention: Life! program intervention (structured group sessions based on the Health Action Process Approach model)
Number of subjects: 796
Study 23369724 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 796
Study 21319914 — intervention group
Group type: EXPERIMENTAL
Intervention: Extinguishing a blocking cue (A-) after training with A+ and AX+
Number of subjects: 0
Study 21319914 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preceding training with blocking cue A)
Number of subjects: 0
Study 20054084 — intervention group
Group type: EXPERIMENTAL
Intervention: Animated model (Group A)
Number of subjects: 74
Study 20054084 — intervention group
Group type: COMPARATOR
Intervention: Text and line drawings (Group B)
Number of subjects: 74
Study 20217203 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg loading dose administered 24 h before PCI)
Number of subjects: 299
Study 16162709 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (hyperpnea training + endurance training)
Number of subjects: 29
Study 16162709 — intervention group
Group type: COMPARATOR
Intervention: Endurance training
Number of subjects: 29
Study 16162709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 29
Study 12095312 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-Phenylbutyrate (Buphenyl) at doses of 20, 30, or 40 g divided t.i.d. for 1 week
Number of subjects: 19
Study 12095312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10726022 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin 50 mg
Number of subjects: 0
Study 10726022 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 0
Study 10726022 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 0
Study 10726022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7774076 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (EPO)
Number of subjects: 67
Study 7774076 — intervention group
Group type: COMPARATOR
Intervention: Control (no EPO)
Number of subjects: 67
Study 2078806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 32
Study 2078806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 38175 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drugs in widespread clinical use for Crohn's disease (specific drugs not mentioned)
Number of subjects: 604
Study 38175 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (adjusted dose based on illness severity)
Number of subjects: 604
Study 38175 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical grading system (CDAI)
Number of subjects: 604
Study 38175 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilcoxon nonparametric statistics and life-table methods for analysis
Number of subjects: 604
Study 38175 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall compliance and completion rates
Number of subjects: 604
Study 12424539 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative immunomagnetic purging
Number of subjects: 20
Study 12424539 — intervention group
Group type: COMPARATOR
Intervention: Unpurged bone marrow support (historical control)
Number of subjects: 20
Study 31614036 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial thickness (ET) measurements
Number of subjects: 38105
Study 30424818 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) programme
Number of subjects: 93
Study 30424818 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality Improvement (QI) intervention
Number of subjects: 93
Study 30424818 — intervention group
Group type: EXPERIMENTAL
Intervention: Care pathway processes
Number of subjects: 93
Study 27775407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup members' emotional expressions (e.g., fearful, happy, neutral)
Number of subjects: 0
Study 27775407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup happy expressions
Number of subjects: 0
Study 27775407 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingroup expressions of fear
Number of subjects: 0
Study 27775407 — intervention group
Group type: COMPARATOR
Intervention: Outgroup emotion trajectories
Number of subjects: 0
Study 24780615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 700‐1000 mg iron (according to calculated iron deficit on postoperative day 2)
Number of subjects: 122
Study 24780615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM)
Number of subjects: 122
Study 24780615 — intervention group
Group type: COMPARATOR
Intervention: Ferrous glycine sulphate (FS) 100 mg iron daily from day 7 onwards
Number of subjects: 122
Study 22700243 — intervention group
Group type: EXPERIMENTAL
Intervention: Proselfs granted voice
Number of subjects: 0
Study 22700243 — intervention group
Group type: EXPERIMENTAL
Intervention: Proselfs denied voice
Number of subjects: 0
Study 22700243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocials granted voice
Number of subjects: 0
Study 22700243 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocials denied voice
Number of subjects: 0
Study 22700243 — intervention group
Group type: COMPARATOR
Intervention: No-voice procedures applied consistently between persons
Number of subjects: 0
Study 20305572 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically elevated teacher ratings of inattentive symptoms
Number of subjects: 79
Study 19102343 — intervention group
Group type: EXPERIMENTAL
Intervention: Straight anastomosis without ileostomy (Group A)
Number of subjects: 256
Study 19102343 — intervention group
Group type: COMPARATOR
Intervention: Straight anastomosis with loop ileostomy (Group B)
Number of subjects: 256
Study 15733766 — intervention group
Group type: EXPERIMENTAL
Intervention: Hands-Off Technique
Number of subjects: 13
Study 15733766 — intervention group
Group type: COMPARATOR
Intervention: Standard Hand Position
Number of subjects: 13
Study 15733766 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-Finger Fulcrum Technique
Number of subjects: 13
Study 15733766 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-Finger Fulcrum Technique
Number of subjects: 13
Study 11805508 — intervention group
Group type: EXPERIMENTAL
Intervention: Microkeratome-based limbal harvester with 170 microm head
Number of subjects: 0
Study 11805508 — intervention group
Group type: EXPERIMENTAL
Intervention: Microkeratome-based limbal harvester with 200 microm head
Number of subjects: 0
Study 11805508 — intervention group
Group type: COMPARATOR
Intervention: Standard microkeratomes for corneal lamellar cuts
Number of subjects: 0
Study 10528328 — intervention group
Group type: EXPERIMENTAL
Intervention: New dopaminergic agonists (carbergolin, pramipexol, ropinirol)
Number of subjects: 0
Study 10528328 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechol-O-methyl-transferase (COMT) inhibitors (entacapone, tolcapone)
Number of subjects: 0
Study 10528328 — intervention group
Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study 10528328 — intervention group
Group type: COMPARATOR
Intervention: Bromocryptin
Number of subjects: 0
Study 7579497 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening (not specified dosage or duration)
Number of subjects: 211
Study 7579497 — intervention group
Group type: COMPARATOR
Intervention: Interview with nonattenders
Number of subjects: 211
Study 1702663 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 micrograms of selenium in high Se malt cakes daily for one year
Number of subjects: 40
Study 1702663 — intervention group
Group type: COMPARATOR
Intervention: Placebo of malt cakes daily for one year
Number of subjects: 40
Study 381876 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 122
Study 381876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 30700615 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided suprainguinal fascia iliaca compartment block (SFICB)
Number of subjects: 60
Study 30700615 — intervention group
Group type: COMPARATOR
Intervention: Periarticular infiltration (PAI)
Number of subjects: 60
Study 30160651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic precursor
Number of subjects: 0
Study 30160651 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine receptor antagonist
Number of subjects: 0
Study 30160651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26739331 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential learning using a transparent shoebox for psychomotor skills followed by a box trainer for knot tying.
Number of subjects: 54